Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
JENA, Germany, Aug. 06, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
-
Announced encouraging results from the Phase II portion of the Phase II/III adaptive, randomized, controlled trial in patients with COVID-19 induced pneumonia, showing a trend in lower 28-day...
-
50% lower all-cause mortality rate and other efficacy trends were shown with IFX-1 in initial data from the randomized exploratory Phase II part of the Phase II/III trialSubject to regulatory...
-
IFX-1 treatment showed a trend in lower 28-day all-cause mortality rate, along with trends of maintained kidney function, faster normalization in lymphocyte counts and greater reduction in LDH in...
-
End of Phase II meeting with the FDA scheduled to discuss the path forward for IFX-1 in Hidradenitis SuppurativaInitial promising results reported in Pyoderma GangraenosumPart 1 of adaptive randomized...
-
End of Phase 2 FDA meeting scheduled to discuss the path forward for IFX-1 in Hidradenitis SuppurativaInitial promising results reported in Pyoderma GangraenosumPart 1 of adaptive randomized trial in...
-
InflaRx has dosed the first patient in an adaptive randomized controlled clinical study with IFX-1 in patients with severe COVID-19 pneumonia in the NetherlandsInflaRx received initial positive human...
-
Two out of the first five patients dosed with IFX-1 achieved complete remissionDose escalation warranted by pharmacodynamic analysis and approved by relevant authorities for a total enrollment of 18...
-
JENA, Germany, Feb. 19, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
-
JENA, Germany, Jan. 09, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...